Market capitalization | $3.20m |
Enterprise Value | $410.00k |
P/E (TTM) P/E ratio | negative |
EV/FCF (TTM) EV/FCF | negative |
P/B ratio (TTM) P/B ratio | 0.86 |
Revenue (TTM) Revenue | $0.00 |
EBIT (operating result TTM) EBIT | $-11.79m |
Free Cash Flow (TTM) Free Cash Flow | $-11.12m |
Cash position | $2.89m |
As a Free StocksGuide user, you can view scores for all 6,883 stocks worldwide.
1 Analyst has issued a forecast Processa Pharmaceuticals Inc:
1 Analyst has issued a forecast Processa Pharmaceuticals Inc:
Sep '24 |
+/-
%
|
||
Revenue | - - |
-
|
|
Gross Profit | - - |
-
|
|
EBITDA | -12 -12 |
19%
19%
|
EBIT (Operating Income) EBIT | -12 -12 |
20%
20%
|
Net Profit | -12 -12 |
47%
47%
|
In millions USD.
If you wish, we will send you an e-mail every morning with news on stocks of your portfolios.
Processa Pharmaceuticals, Inc. engages in the discovery, development, and commercialization of drug products for the treatment of serious medical conditions. Its product pipeline is PCS499, which is use for the treatment of Necrobiosis Lipoidica. The company was founded by David Young, Patrick Lin, Sian E. Bigora, Wendy Guy, and Chang Rung Chen on October 2, 2017 and is headquartered in Hanover, MD.
Head office | United States |
CEO | George Ng |
Employees | 13 |
Founded | 2011 |
Website | www.processapharmaceuticals.com |
StocksGuide is the ultimate tool for easily finding, analyzing and tracking stocks. Learn from successful investors and make informed investment decisions. We empower you to become a confident, independent investor.